Cargando…

First mitochondrial genome-wide association study with metabolomics

In the era of personalized medicine with more and more patient-specific targeted therapies being used, we need reliable, dynamic, faster and sensitive biomarkers both to track the causes of disease and to develop and evolve therapies during the course of treatment. Metabolomics recently has shown su...

Descripción completa

Detalles Bibliográficos
Autores principales: Aboulmaouahib, Brahim, Kastenmüller, Gabi, Suhre, Karsten, Zöllner, Sebastian, Weissensteiner, Hansi, Prehn, Cornelia, Adamski, Jerzy, Gieger, Christian, Wang-Sattler, Rui, Lichtner, Peter, Strauch, Konstantin, Flaquer, Antònia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9523559/
https://www.ncbi.nlm.nih.gov/pubmed/34718574
http://dx.doi.org/10.1093/hmg/ddab312
Descripción
Sumario:In the era of personalized medicine with more and more patient-specific targeted therapies being used, we need reliable, dynamic, faster and sensitive biomarkers both to track the causes of disease and to develop and evolve therapies during the course of treatment. Metabolomics recently has shown substantial evidence to support its emerging role in disease diagnosis and prognosis. Aside from biomarkers and development of therapies, it is also an important goal to understand the involvement of mitochondrial DNA (mtDNA) in metabolic regulation, aging and disease development. Somatic mutations of the mitochondrial genome are also heavily implicated in age-related disease and aging. The general hypothesis is that an alteration in the concentration of metabolite profiles (possibly conveyed by lifestyle and environmental factors) influences the increase of mutation rate in the mtDNA and thereby contributes to a range of pathophysiological alterations observed in complex diseases. We performed an inverted mitochondrial genome-wide association analysis between mitochondrial nucleotide variants (mtSNVs) and concentration of metabolites. We used 151 metabolites and the whole sequenced mitochondrial genome from 2718 individuals to identify the genetic variants associated with metabolite profiles. Because of the high coverage, next-generation sequencing-based analysis of the mitochondrial genome allows for an accurate detection of mitochondrial heteroplasmy and for the identification of variants associated with the metabolome. The strongest association was found for mt715(G > A) located in the MT-12SrRNA with the metabolite ratio of C2/C10:1 (P-value = 6.82(*)10(−09), β = 0.909). The second most significant mtSNV was found for mt3714(A > G) located in the MT-ND1 with the metabolite ratio of phosphatidylcholine (PC) ae C42:5/PC ae C44:5 (P-value = 1.02(*)10(−08), β = 3.631). A large number of significant metabolite ratios were observed involving PC aa C36:6 and the variant mt10689(G > A), located in the MT-ND4L gene. These results show an important interconnection between mitochondria and metabolite concentrations. Considering that some of the significant metabolites found in this study have been previously related to complex diseases, such as neurological disorders and metabolic conditions, these associations found here might play a crucial role for further investigations of such complex diseases. Understanding the mechanisms that control human health and disease, in particular, the role of genetic predispositions and their interaction with environmental factors is a prerequisite for the development of safe and efficient therapies for complex disorders.